摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-3-(4-(2,2,2-trifluoroethoxy)phenyl)acrylic acid | 1268243-15-7

中文名称
——
中文别名
——
英文名称
(E)-3-(4-(2,2,2-trifluoroethoxy)phenyl)acrylic acid
英文别名
(E)-3-[4-(2',2',2'-trifluoroethoxy)phenyl]prop-2-enoic acid;(E)-3-[4-(2,2,2-trifluoroethoxy)phenyl]prop-2-enoic acid
(E)-3-(4-(2,2,2-trifluoroethoxy)phenyl)acrylic acid化学式
CAS
1268243-15-7
化学式
C11H9F3O3
mdl
MFCD11200567
分子量
246.186
InChiKey
XVPLDBHSEDUMPC-ZZXKWVIFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.181
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (E)-3-(4-(2,2,2-trifluoroethoxy)phenyl)acrylic acid盐酸肼屈嗪1-羟基苯并三唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 24.0h, 以66%的产率得到(2E,N',E)-3-[4-(2',2',2'-trifluoroethoxy)phenyl]-N'-[phthalazin-1-(2H)-ylidiene]acrylohydrazide
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of New Cinnamic Derivatives as Antituberculosis Agents
    摘要:
    Tuberculosis, HIV coinfection with TB, emergence of multidrug-resistant TB, and extensively drug-resistant TB are the major causes of death from infectious diseases worldwide. Because no new drug has been introduced in the last several decades, new classes of molecules as anti-TB drugs are urgently needed. Herein, we report the synthesis and structure-activity relationships of a series of thioester, amide, hydrazide, and triazolophthalazine derivatives of 4-alkoxy cinnamic acid. Many compounds exhibited submicromolar minimum inhibitory concentrations against Mycobacterium tuberculosis strain (H(37)Rv). Interestingly, compound 13e, a 4-isopentenyloxycinnamyl triazolophthalazine derivative, was found to be 100-1800 times more active than isoniazid (INH) when tested for its ability to inhibit the growth of INH-resistant M. tuberculosis strains. The results also revealed that 13e does not interfere with mycolic acid biosynthesis, thereby pointing to a different mode of action and representing an attractive lead compound for the development of new anti-TB agents.
    DOI:
    10.1021/jm101510d
  • 作为产物:
    描述:
    methyl (E)-3-(4-(2,2,2-trifluoroethoxy)phenyl)acrylatepotassium carbonate 作用下, 以 甲醇 为溶剂, 反应 3.0h, 以100%的产率得到(E)-3-(4-(2,2,2-trifluoroethoxy)phenyl)acrylic acid
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of New Cinnamic Derivatives as Antituberculosis Agents
    摘要:
    Tuberculosis, HIV coinfection with TB, emergence of multidrug-resistant TB, and extensively drug-resistant TB are the major causes of death from infectious diseases worldwide. Because no new drug has been introduced in the last several decades, new classes of molecules as anti-TB drugs are urgently needed. Herein, we report the synthesis and structure-activity relationships of a series of thioester, amide, hydrazide, and triazolophthalazine derivatives of 4-alkoxy cinnamic acid. Many compounds exhibited submicromolar minimum inhibitory concentrations against Mycobacterium tuberculosis strain (H(37)Rv). Interestingly, compound 13e, a 4-isopentenyloxycinnamyl triazolophthalazine derivative, was found to be 100-1800 times more active than isoniazid (INH) when tested for its ability to inhibit the growth of INH-resistant M. tuberculosis strains. The results also revealed that 13e does not interfere with mycolic acid biosynthesis, thereby pointing to a different mode of action and representing an attractive lead compound for the development of new anti-TB agents.
    DOI:
    10.1021/jm101510d
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL ANTI-FIBROTIC DRUGS<br/>[FR] NOUVEAUX MÉDICAMENTS ANTI-FIBROTIQUES
    申请人:[en]HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
    公开号:WO2022258792A1
    公开(公告)日:2022-12-15
    The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever and pericarditis. Further, the invention relates to a pharmaceutical composition comprising said cinnamic acid amides and to a screening essay for identifying compounds suitable for the treatment of fibrosis.
  • Design, Synthesis, and Biological Evaluation of New Cinnamic Derivatives as Antituberculosis Agents
    作者:Prithwiraj De、Georges Koumba Yoya、Patricia Constant、Florence Bedos-Belval、Hubert Duran、Nathalie Saffon、Mamadou Daffé、Michel Baltas
    DOI:10.1021/jm101510d
    日期:2011.3.10
    Tuberculosis, HIV coinfection with TB, emergence of multidrug-resistant TB, and extensively drug-resistant TB are the major causes of death from infectious diseases worldwide. Because no new drug has been introduced in the last several decades, new classes of molecules as anti-TB drugs are urgently needed. Herein, we report the synthesis and structure-activity relationships of a series of thioester, amide, hydrazide, and triazolophthalazine derivatives of 4-alkoxy cinnamic acid. Many compounds exhibited submicromolar minimum inhibitory concentrations against Mycobacterium tuberculosis strain (H(37)Rv). Interestingly, compound 13e, a 4-isopentenyloxycinnamyl triazolophthalazine derivative, was found to be 100-1800 times more active than isoniazid (INH) when tested for its ability to inhibit the growth of INH-resistant M. tuberculosis strains. The results also revealed that 13e does not interfere with mycolic acid biosynthesis, thereby pointing to a different mode of action and representing an attractive lead compound for the development of new anti-TB agents.
查看更多